Abstract
Parkinson's disease (PD) is the most prevalent movement disorder in the world. The major pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies. At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching for neuroprotective agents and disease modifying strategies to slow the progress of neurodegeneration. However, due to lack of data about the main pathological sequence of PD, many drug targets failed to provide neuroprotective effects in human trials. Recent evidence suggests the involvement of C-Abelson (c-Abl) tyrosine kinase enzyme in the pathogenesis of PD. Through parkin inactivation, alpha synuclein aggregation, and impaired autophagy of toxic elements. Experimental studies showed that (1) c-Abl activation is involved in neurodegeneration and (2) c-Abl inhibition shows neuroprotective effects and prevents dopaminergic neuronal' death. Current evidence from experimental studies and the first in-human trial shows that c-Abl inhibition holds the promise for neuroprotection against PD and therefore, justifies the movement towards larger clinical trials. In this review article, we discussed the role of c-Abl in PD pathogenesis and the findings of preclinical experiments and the first in-human trial. In addition, based on lessons from the last decade and current preclinical evidence, we provide recommendations for future research in this area.
Keywords: Alzheimer's disease, c-Abelson, nilotinib, Parkinson's disease, tyrosine kinase inhibitors, neurological diseases.
CNS & Neurological Disorders - Drug Targets
Title:C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease
Volume: 17 Issue: 1
Author(s): Abdelrahman Ibrahim Abushouk, Ahmed Negida*, Rasha Abdelsalam Elshenawy, Hossam Zein, Ali M. Hammad, Ahmed Menshawy and Wael M.Y. Mohamed
Affiliation:
- Medical Research Group of Egypt, Zagazig, El-Sharkia,Egypt
Keywords: Alzheimer's disease, c-Abelson, nilotinib, Parkinson's disease, tyrosine kinase inhibitors, neurological diseases.
Abstract: Parkinson's disease (PD) is the most prevalent movement disorder in the world. The major pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies. At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching for neuroprotective agents and disease modifying strategies to slow the progress of neurodegeneration. However, due to lack of data about the main pathological sequence of PD, many drug targets failed to provide neuroprotective effects in human trials. Recent evidence suggests the involvement of C-Abelson (c-Abl) tyrosine kinase enzyme in the pathogenesis of PD. Through parkin inactivation, alpha synuclein aggregation, and impaired autophagy of toxic elements. Experimental studies showed that (1) c-Abl activation is involved in neurodegeneration and (2) c-Abl inhibition shows neuroprotective effects and prevents dopaminergic neuronal' death. Current evidence from experimental studies and the first in-human trial shows that c-Abl inhibition holds the promise for neuroprotection against PD and therefore, justifies the movement towards larger clinical trials. In this review article, we discussed the role of c-Abl in PD pathogenesis and the findings of preclinical experiments and the first in-human trial. In addition, based on lessons from the last decade and current preclinical evidence, we provide recommendations for future research in this area.
Export Options
About this article
Cite this article as:
Abushouk Ibrahim Abdelrahman, Negida Ahmed *, Elshenawy Abdelsalam Rasha , Zein Hossam , Hammad M. Ali , Menshawy Ahmed and Mohamed M.Y. Wael , C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease, CNS & Neurological Disorders - Drug Targets 2018; 17 (1) . https://dx.doi.org/10.2174/1871527316666170602101538
DOI https://dx.doi.org/10.2174/1871527316666170602101538 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Clinical Application of Infrared Thermal Imaging in Lumbocrural Pain
Current Medical Imaging Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry Identifying Coevolution Between Amino Acid Residues in Protein Families: Advances in the Improvement and Evaluation of Correlated Mutation Algorithms
Current Bioinformatics Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Rolipram Rescues Memory Consolidation Deficits Caused by Sleep Deprivation: Implication of the cAMP/PKA and cAMP/Epac Pathways
CNS & Neurological Disorders - Drug Targets New Perspectives in the Management of Post-Surgical Macular Edema
Recent Patents on Drug Delivery & Formulation Suppression of Inflammatory and Allergic Responses by Pharmacologically Potent Fungus Ganoderma lucidum
Recent Patents on Inflammation & Allergy Drug Discovery Novel Penetrating Cations for Targeting Mitochondria
Current Pharmaceutical Design Post-stroke Engagement-sensitive Balance Rehabilitation Under An Adaptive Multi-level Electrotherapy: Clinical Hypothesis and Computational Framework
Neuroscience and Biomedical Engineering (Discontinued) Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry Phenotypes of Obstructive Sleep Apnea and Direct Targeted Therapy: A Literature Review
Current Respiratory Medicine Reviews Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Glucokinase Activators for the Potential Treatment of Type 2 Diabetes
Current Topics in Medicinal Chemistry From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Current Understanding of the Interplay Between Catechol-OMethyltransferase Genetic Variants, Sleep, Brain Development and Cognitive Performance in Schizophrenia
CNS & Neurological Disorders - Drug Targets Creatine Supplementation: Can it Improve Quality of Life in the Elderly without Associated Resistance Training?
Current Aging Science Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry